[1] Andell P, Li X, Martinsson A, et al.Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study[J]. Heart, 2017, 103(21):1696-1703.
[2] 马超,王辉山,韩劲松,等.心脏瓣膜假体植入和外科消融迷宫手术治疗瓣膜病合并心房颤动[J]. 中国组织工程研究, 2020, 24(28):4580-4587.
[3] 宋建敏,陈灿.射频消融术联合瓣膜置换术治疗心脏瓣膜病合并房颤的疗效及对心功能和术后转复率的影响[J]. 中西医结合心脑血管病杂志, 2019, 17(17):2655-2658.
[4] Epstein AE, Olshansky B, Naccarelli GV, et al.Practical management guide for clinicians who treat patients with amiodarone[J]. Am J Med, 2016, 129(5):468-475.
[5] 覃少洲. 胺碘酮治疗风湿性心脏病瓣膜置换术后心房颤动[J].中西医结合心脑血管病杂志, 2013, 11(1):114-115.
[6] Nishimura RA, Otto CM, Bonow RO, et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(22):157-185.
[7] Mathew JP, Fontes ML, Tudor IC, et al.A multicenter risk index for atrial fibrillation after cardiac surgery[J]. JAMA, 2004, 291(14):1720-1729.
[8] 周冬冬,姜亦瑶,袁超,等.风湿性心脏瓣膜病合并心房颤动中胶原蛋白表达与分布[J]. 广东医学, 2017, 38(14):2147-2150.
[9] Balik M, Waldauf P, Maly M, et al.Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study[J]. BMJ Open, 2019, 9(9):31678.
[10] 胺碘酮规范应用专家建议专家写作组. 胺碘酮规范应用专家建议[J]. 中华内科杂志, 2019, 58(4):258-264.
[11] 冯智娟,陆成炜,李正章.不同剂量胺碘酮联合缬沙坦对风湿性心脏瓣膜置换术后持续性房颤患者心功能和NT-proBNP水平的影响[J]. 检验医学与临床, 2018, 15(17):2624-2627.
[12] 张帆,洪丽荣.胺碘酮相关甲状腺功能障碍的诊治[J]. 中国实用内科杂志, 2019, 39(4):336-341. |
